Celon Pharma S.A. (CLN.WA)
- Previous Close
24.30 - Open
24.15 - Bid 23.75 x --
- Ask 23.85 x --
- Day's Range
23.75 - 24.45 - 52 Week Range
15.14 - 32.90 - Volume
11,230 - Avg. Volume
51,037 - Market Cap (intraday)
1.284B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
72.27 - EPS (TTM)
0.33 - Earnings Date May 21, 2025
- Forward Dividend & Yield 0.08 (0.33%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
27.64
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
www.celonpharma.com562
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CLN.WA
View MorePerformance Overview: CLN.WA
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLN.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLN.WA
View MoreValuation Measures
Market Cap
1.31B
Enterprise Value
1.22B
Trailing P/E
73.64
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.25
Price/Book (mrq)
2.54
Enterprise Value/Revenue
6.78
Enterprise Value/EBITDA
15.11
Financial Highlights
Profitability and Income Statement
Profit Margin
8.83%
Return on Assets (ttm)
2.29%
Return on Equity (ttm)
3.79%
Revenue (ttm)
209.54M
Net Income Avi to Common (ttm)
18.51M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
103.28M
Total Debt/Equity (mrq)
2.78%
Levered Free Cash Flow (ttm)
33.51M